



Dulera[®] (mometasone furoate/formoterol fumarate dihydrate) – Expanded indication, new strength

- On August 12, 2019, the [FDA approved](#) Merck's [Dulera \(mometasone furoate/ formoterol fumarate dihydrate\)](#) inhalation aerosol, for the twice-daily treatment of asthma in patients 5 years of age and older.
 - Dulera was previously approved for this indication in patients 12 years of age and older.
 - Dulera should be used for patients not adequately controlled on a long-term asthma-control medication such as an inhaled corticosteroid (ICS) or whose disease warrants initiation of treatment with both an ICS and long-acting beta₂-adrenergic agonist.
 - Dulera is not indicated for the relief of acute bronchospasm.
- The FDA also approved a Dulera 50 mcg/5 mcg strength (per actuation) for use in pediatric patients aged 5 to less than 12 years. Dulera was previously available in a 100 mcg/5 mcg or 200 mcg/5 mcg strength.
- The approval of Dulera for the expanded indication was based on an active-controlled study in 181 asthma patients aged 5 to less than 12 years. Patients received Dulera or mometasone furoate metered dose inhaler 50 mcg (MDI).
 - Primary endpoint results showed that patients receiving Dulera had a statistically significant change from baseline to week 12 in 60-min AM post-dose % predicted FEV₁ compared to mometasone furoate MDI 50 mcg (5.21, 95% CI: 3.22, 7.20).
- The recommended dose of Dulera for the treatment of asthma in pediatric patients aged 5 to less than 12 years is two inhalations of Dulera 50 mcg/5 mcg twice daily. The maximum daily dosage is 200 mcg/20 mcg.
 - Refer to the Dulera drug label for dosing for patients 12 years and older.
- Merck's launch plans for the 50 mcg/5 mcg strength of Dulera are pending.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.